TiumBio’s Post

A new meta-analysis comparing iv vs pn dexamethasone for the intescalene brachial plexus block [https://lnkd.in/e6_zqdfs]. In brief, there is low-quality evidence that perineural administration of dexamethasone as a local anaesthetic adjunct increases duration of analgesia by an average of 2 h compared with intravenous injection for interscalene brachial plexus block. Given the limited clinical relevance of this difference, the off-label use of perineural administration, and the risk of drug crystallisation, we recommend intravenous dexamethasone administration.

Potentially lost in some of the big gastroenterology data releases at DDW last week were the announced phase 2 findings for etrasimod (known as Velsipity in ulcerative colitis) in eosinophilic esophagitis (EoE). The data show etrasimod efficacy in terms of eosinophil reduction (primary endpoint), but also in terms of symptom improvement (Dysphagia Symptom Questionnaire scores). While a potential launch is still a while away, strong performance on both those measures, plus the oral formulation should help etrasimod have success in this market. Etrasimod will try to model the successful launch that Dupixent has had in EoE, but differentiate based on oral vs. injectable formulation. #gastroenterology #clinicaldata https://lnkd.in/ePUKcavH

Ophthopedia Update:To Treat or Not to Treat Geographic Atrophy – That is the Question: To treat or not to treat – that is the question for patients with geographic atrophy and the physicians entrusted with their care. This is a timely question because our profession finds itself enmeshed in a legitimate debate about the role of complement inhibition in the treatment of geographic atrophy.1–3 This debate arises from our own success, as 2 complement inhibitory drugs have been recently approved by the U.S. Food and Drug Administration, pegcetacoplan and avacincaptad pegol.4–6 Monthly intravitreal avacincaptad pegol reduced the mean square-root-transformed geographic atrophy area growth rate by 14% at 1 year (2 mg dose) and by 28.1% (2 mg cohort) and 30.0% (4 mg cohort) at 18 months versus sham. #Ophthalmology #Retina #Ophthotwitter

H2H study of secukinumab vs adalimumab biosimilar in axial-SpA pts saw no difference & little change in Xray progression for both Rxs. 859 pts showed no signif diff w/ NO Xray progr (66%, 67%, 66%) or mSASSS (0.54, 0.55, 0.72) change

ICYMI: Cornea Update: Stability and Sterility of Extemporaneously Prepared Nonpreserved Cefazolin, Ceftazidime, Vancomycin, Amphotericin B, and Methylprednisolone Eye Drops: Purpose: To determine in-use stability and sterility of fortified cefazolin, ceftazidime, vancomycin, amphotericin B, and methylprednisolone eye drops in a simulated inpatient setting with and without a mobile refrigerated container (MR). Methods: Each drug was prepared and divided into 4 groups: 1) simulated patient use with the MR group: stored at 4°C and kept in the MR during drug administration, 2) simulated patient use without the MR (NoMR) group: stored at 4°C and no MR, 3) refrigerated control group: stored at 4°C, and 4) room temperature control group: stored at room temperature. Stability and sterility data were evaluated at days 0, 4, 7, 14, 21, and 28. Linear mixed-effects model and survival analysis were performed. Results: Median time to 10% loss of concentration for in-use medications (MR/NoMR groups) was >28/27.9, 22.2/22.2, 19.4/19.4, 10.18/28/>28 days for cefazolin, ceftazidime, vancomycin, amphotericin B, and methylprednisolone, respectively. There was no significant difference in the predicted concentration loss per day among all groups for vancomycin and methylprednisolone (all P > 0.05). For the other study medications, all room temperature control groups, the cefazolin NoMR group, and the ceftazidime NoMR group had significantly greater predicted concentration loss per day compared with the refrigerated control groups (all P ≤ 0.02). Culture results were negative for all drugs throughout the study. Conclusions: The NoMR group showed that the drug significantly degraded rapidly for cefazolin, ceftazidime, and amphotericin B. Implementation of MR could decrease the predicted loss of concentration per day for cefazolin and ceftazidime. In vitro antimicrobial activity and sterility were retained for 28 days. http://dlvr.it/T0nxB9 #Cornea #MostPopularArticles #Ophthalmology

Efficiency of Hyaluronic Acid Versus Red Injectable Platelet-Rich Fibrin (I-PRF) in Treatment of Stage III Periodontitis: Randomized Controlled Clinical Trial

H2H study of secukinumab vs adalimumab biosimilar in axial-SpA pts saw no difference & little change in Xray progression for both Rxs. 859 pts showed no signif diff w/ NO Xray progr (66%, 67%, 66%) or mSASSS (0.54, 0.55, 0.72) change

ICYMI: Cornea Update: Stability and Sterility of Extemporaneously Prepared Nonpreserved Cefazolin, Ceftazidime, Vancomycin, Amphotericin B, and Methylprednisolone Eye Drops: Purpose: To determine in-use stability and sterility of fortified cefazolin, ceftazidime, vancomycin, amphotericin B, and methylprednisolone eye drops in a simulated inpatient setting with and without a mobile refrigerated container (MR). Methods: Each drug was prepared and divided into 4 groups: 1) simulated patient use with the MR group: stored at 4°C and kept in the MR during drug administration, 2) simulated patient use without the MR (NoMR) group: stored at 4°C and no MR, 3) refrigerated control group: stored at 4°C, and 4) room temperature control group: stored at room temperature. Stability and sterility data were evaluated at days 0, 4, 7, 14, 21, and 28. Linear mixed-effects model and survival analysis were performed. Results: Median time to 10% loss of concentration for in-use medications (MR/NoMR groups) was >28/27.9, 22.2/22.2, 19.4/19.4, 10.18/28/>28 days for cefazolin, ceftazidime, vancomycin, amphotericin B, and methylprednisolone, respectively. There was no significant difference in the predicted concentration loss per day among all groups for vancomycin and methylprednisolone (all P > 0.05). For the other study medications, all room temperature control groups, the cefazolin NoMR group, and the ceftazidime NoMR group had significantly greater predicted concentration loss per day compared with the refrigerated control groups (all P ≤ 0.02). Culture results were negative for all drugs throughout the study. Conclusions: The NoMR group showed that the drug significantly degraded rapidly for cefazolin, ceftazidime, and amphotericin B. Implementation of MR could decrease the predicted loss of concentration per day for cefazolin and ceftazidime. In vitro antimicrobial activity and sterility were retained for 28 days. http://dlvr.it/T15bFs #Cornea #MostPopularArticles #Ophthalmology

🌟 EXPERT INSIGHTS: Alumis recently announced it has commenced patient dosing in its ONWARD phase 3 clinical program evaluating ESK-001, an oral allosteric TYK2 inhibitor, for moderate to severe plaque #psoriasis. Martin Babler, CEO of Alumis, recently discussed the significance of this clinical program and the potential of ESK-001 in the psoriasis treatment landscape. 🖇 Read more now: https://lnkd.in/g7Z_n2ib

📣 Biopôle members LASCCO SA and Abionic have announced a new licensing agreement with global #LifeSciences company Fapon. The deal will pave the way to use of the pancreatic stone protein (PSP) marker for sepsis diagnosis in China. 🧪 Since 2015, LASCCO has partnered with Abionic to develop PSP testing on high-risk patients for early diagnosis of sepsis – sometimes even before the onset of clinical symptoms. This #MedicalBreakthrough reduces the risk of organ dysfunction, improves survival rates and optimises the use of #healthcare resources. The PSP test has already been deployed in over 20 countries. Under the new agreement, Fapon will bring it to the Chinese market. 👉 Read the full story: https://lnkd.in/eSHND9XD